Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress

Fig. 1

Expression levels of Cyr61 in ascites and serum of ovarian benign and malignant tumor Cyr61 levels in ascites and serum of ovarian serous adenocarcinoma patients (n = 66) were significantly higher than those of ovarian serous cystadenoma patients (n = 18). And the ascites Cyr61 level was much higher than that of serum

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us